LARS2 and colorectal carcinoma: found that leucine-tRNA-synthetase-2 (LARS2)-expressing B cell (LARS B) with TGF-β1-dominant feature correlates with shortened survival in CRC, mechanistically, LARS2 programmed mitochondrial nicotinamide adenine dinucleotide (NAD+) regeneration and oxidative metabolism, thus determining the regulatory feature of LARS B cells in which the NAD-dependent protein deacetylase sirtuin-1 (SIRT1) was involved (77).